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Abstract
The U3 region of the LTR of oncogenic Moloney murine leukemia virus (Mo-MuLV) and feline leukemia viruses (FeLV) have been
previously reported to activate expression of specific cellular genes in trans, such as MHC class I, collagenase IV, and MCP-1, in an
integration-independent manner. It has been suggested that transactivation of these specific cellular genes by leukemia virus U3-LTR may
contribute to the multistage process of leukemogenesis. The U3-LTR region, necessary for gene transactivational activity, also contains
multiple transcription factor-binding sites that are essential for normal virus replication. To dissect the promoter activity and the gene
transactivational activity of the U3-LTR, we conducted mutational analysis of the U3-LTR region of FeLV-A molecular clone 61E. We
identified minimal nucleotide substitution mutants on the U3 LTR that did not disturb transcription factor-binding sites but abrogated its
ability to transactivate the collagenase gene promoter. To determine if these mutations actually have altered any uncharacterized important
transcription factor-binding site, we introduced these U3-LTR mutations into the full-length infectious molecular clone 61E. We demon-
strate that the mutant virus was replication competent but could not transactivate cellular gene expression. These results thus suggest that
the gene transactivational activity is a distinct property of the LTR and possibly not related to its promoter activity. The cellular gene
transactivational activity-deficient mutant FeLV generated in this study may also serve as a valuable reagent for testing the biological
significance of LTR-mediated cellular gene activation in the tumorigenesis caused by leukemia viruses.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Feline leukemia viruses (FeLVs) are oncogene-deficient
retroviruses associated with various neoplastic and degenera-
tive diseases in domestic cats, of which T cell lymphoma is the
most common (Hoover and Mullins, 1991; Rezanka et al.,
1992). Both viral genetics and virus–host interactions are crit-
ical in determining the disease outcome following FeLV in-
fection. Although the exact pathogenic mechanism by which
these viruses induce tumor in infected animals is not known, it
is generally believed that, similar to murine leukemia viruses
(MuLV), insertional activation of cellular protooncogenes fol-
lowing provirus integration is the major late determinant of
disease induction. Several earlier studies have established that
transcriptional enhancers present within the U3 region of the
long terminal repeats (LTRs) of MuLVs and FeLVs are im-
portant determinants for their tissue tropism and tumorigenic
potential (Chatis et al., 1984; DesGroseillers and Jolicoeur,
1984; Lenz et al., 1984; Speck et al., 1990). The enhancer
element of MuLV and FeLVs contain binding sites for various
transcription factors. Because of selective expression of tran-
scription factors in different tissues, these enhancer elements
can influence tissue tropism, disease specificity, and patho-
genic potential (Golemis et al., 1989; Short et al., 1987;
Zaiman et al., 1995, 1998). Studies on recombinant viruses
have shown that reciprocal exchange of the LTR (or the en-
hancer region) between Friend-MuLV (F-MuLV) and Molo-
ney-MuLV (Mo-MuLV) leads to altered disease specificity of
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the viruses (Chatis et al., 1984). Mo-MuLV with an F-MuLV
LTR enhancer induces erythroleukemia instead of T lym-
phoma and vice versa. Duplication of the U3 enhancer region
has also been detected frequently and shown to be closely
related to leukemogenesis (Matsumoto et al., 1992; Rohn and
Overbaugh, 1995).
We have previously demonstrated that LTRs from onco-
genic Mo-MuLV and FeLVs can activate expression of spe-
cific cellular genes, such as collagenase IV, MCP-1, and class
I MHC in an integration-independent fashion (Faller et al.,
1997a,b; Flyer et al., 1985; Ghosh and Faller, 1999). This
activation takes place at the level of transcription and is inde-
pendent of physical location of the viral genome or the respon-
sive cellular genes and is thus a trans effect (Wilson et al.,
1987). Because of the potential importance of these cellular
genes in tumor promotion and progression, we have suggested
that this gene transactivational activity of leukemia virus LTRs
may play a role in tumor induction by these viruses. This
hypothesis was further supported by the demonstration that
LTRs from nonleukemogenic FeLVs are unable to induce
cellular gene activation (Ghosh et al., 2000). We have reported
that U3-LTR region alone is sufficient for the gene transacti-
vational activity. We have also reported that the U3-LTR
region sufficient for the gene transactivational property does
not encode any open reading frame of appreciable length in
either a positive or a negative orientation.
Although we have convincingly demonstrated the cellular
gene transactivation activity of leukemogenic MuLV and
FeLV LTRs, the molecular mechanism of the process and its
biological significance in leukemogenesis has not yet been
tested. The U3-LTR region necessary for cellular gene trans-
activational property also contains multiple transcription fac-
tor-binding sites that are essential for normal virus replication.
We do not know whether the cellular gene transactivational
activity and the promoter activity of the LTR are governed by
same or different determinants on the U3-LTR. To dissect
these two functions of the LTR, we wanted to test if any
U3-LTR sequence other than the transcription factor-binding
sites on them have any necessary role for gene transactiva-
tional activity. Here we report the generation of mutant FeLV
LTRs which lack transactivational activity, but without mod-
ification of the known critical transcription factor-binding sites.
We have reconstructed full-length FeLV containing these LTR
mutations and have found that the LTR-mutant full-length
virus no longer transactivates cellular gene expression, yet is
replication competent. Thus the transactivational activity mu-
tants do not interfere with the promoter activity of the LTR.
Results
Identification of the minimal U3-LTR region sufficient for
gene transactivation activity
To determine which region of the LTR to use for muta-
tional analysis, we first determined the minimal LTR region
sufficient for cellular gene transactivational activity. We
made several 5- and 3-end deletion constructs of FeLV
U3-LTR by PCR amplification using custom-made oligo-
nucleotide primers. Suitable restriction enzyme recognition
sites were introduced in these primers by minimal sequence
alteration. The template in these PCR reactions was U3-
LTR clone 61E-LTR, which contains the FeLV-A infec-
tious molecular clone 61E sequence from 307 to 34
(where 1 is the beginning of R-region) (Donahue et al.,
1988; Ghosh and Faller, 1999). Four primers (P2, M5, M6,
and M7), in combination with forward and reverse universal
primers, generated eight different PCR fragments. Nucleo-
tide sequences of these primers are shown in Table 1 and
relative positions of these fragments along the LTR are
shown in Fig. 1. A total of eight U3-LTR subclones with
sizes between 100 and 280 bp were generated from these
PCR fragments. Inserts of the representative clones were
sequenced in their entirety to verify absence of any PCR-
introduced error. The transactivational activity of these
smaller LTR subclones were then analyzed in cotransfection
experiments with 517/62 coll-CAT reporter plasmid in
Balb-3T3 cells. The LTR sequence in clone H was found to
be the smallest region sufficient for strong transactivation of
the collagenase IV promoter (Fig. 1). The level of induction
of collagenase IV gene expression was 39.6-fold over back-
ground and was comparable to the induction level of paren-
tal clone 61E-LTR (28.4-fold). Clone H contained FeLV-A
U3-LTR sequences from 248 to 39. Comparison of the
activity of the clones C, E, F, and G to that of the clones D
and H clearly indicated that the region from 248 to 222
(the region between primers M5 and P2) and from 119 to
39 (the region between M6 and M7) were absolutely
necessary for the activity. It is also noteworthy that the LTR
region from 39 to 30 (the region between M7 and
3-end of these clones) appears to have some inhibitory
effect on the gene transactivational activity of the LTR
(compare clone B with clone H in Fig. 1).
LTR substitution mutants without gene transactivational
activity
Once we identified a relatively small region of the U3-
LTR sufficient for transactivational activity, we wished to
make small substitution mutations in this region. Since our
goal was to dissect the LTR’s transactivational activity and
promoter activity, we selected those regions for mutation
that would not overlap with any of the transcription factor-
binding sites. Further we also considered the fact that this
region of the LTR makes a specific RNA transcript whose
synthesis is closely related to its transactivational activity
(Choi and Faller, 1995; Ghosh et al., 2000). We analyzed
the predicted secondary structure of the RNA transcript
from the U3-LTR region. Although we do not know the
precise boundaries of the transcript or whether any partic-
ular secondary structure is important for transactivation, we
selected those regions for mutation where changes would
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affect base-pairing in the secondary structure of the tran-
script and destabilize it. Initially, we identified seven re-
gions that were not known as transcription factor-binding
sites and yet could significantly alter predicted RNA sec-
ondary structure. These regions (designated H-A, H-D, H-1,
H-2, H-3, and H-4) and the 2–4 base substitution mutations
Table 1
Sequences of the primers used in reverse transcription and polymerase chain reactions in this study
Primer
name
Sequence (5–3)a Location on
FeLV-61Eb
Enzyme site Strand
M5 GTTCCCATGgGATcCAAGGAA 262 to 242 BamHI 
M6 ACTGGGGAGCtcGGAGACTGC 107 to 127 SstI 
M7 ATAGCAGAAttCGCGCGTACA 28 to 48 EcoRI 
M10 ATTGGTTAGTTTAAATGAGGC 67 to 87 None 
P1 AACCCAACAGTACCAACAGAT 7521 to 7541 None 
P2 AGGATATCTGTGGTTAAGCAC 226 to 206 EcoRV 
P3 AGTCTCAGCAAAGACTTGCGC 21 to 1 None 
P8 ACGGGTACCCGGGGCGGTCAA 73 to 53 SmaI/KpnI 
HA-F ACCCtGatgcTAGCTGAAACAGCAGAAGTT 173 to 144 None 
HA-R GCTAgcatCaGGGTTTAACTGTTCTTGGCC 144 to 173 None 
HD-F GTCTCCgacgTCCCCAGTTGACCAGAG 125 to 99 None 
HD-R TGGGGAcgtcGGAGACTGCTGGCAGCG 99 to 125 None 
H1-F AACAGCAGAAacTTCAAGGCCGCTGCC 156 to 130 None 
H1-R GGCAGCGGCCTTGAAgtTTCTGCTGTT 130 to 156 None 
H2-F CAGCAGTCTCCtccgTCCCCAGTTGAC 130 to 104 None 
H2-R GTCAACTGGGGAcggaGGAGACTGCTG 104 to 130 None 
H3-F CAGGCTCCCCAGTTctCCAGAGTTCGA 120 to 94 None 
H3-R TCGAACTCTGGagAACTGGGGAGCCTG 94 to 120 None 
H4-F TCTTCAAGGCCcgaGCCAGCAGTCTCC 146 to 120 None 
H4-R GGAGACTGCTGGCtcgGGCCTTGAAGA 120 to 146 None 
D1 ttgcatgcCTGCAGcacaGCCATTTCAC 307 to 288 SphI/PstI 
D2 ttgcatgcCTGCAGTGGTGCCATgatgCAAGGCAT 307 to 281 SphI/PstI 
D3 ttgcatgcCTGCAGTGGTGCCATTTCACAAGGCgcacAAAATTAC 307 to 271 SphI/PstI 
D4 ttgcatgcCTGCAGTGGTGCCATTTCACAAGGCATGGAAAATTttgaAAGTATGT 307 to 261 SphI/PstI 
D5 gcatgcCTGCAGTGGTGCCATTTCACAAGGCATGGAAAATTACTCAAGTATtacgCCATG 307 to 254 SphI/PstI 
a Bold letters indicate a restriction enzyme site, whereas lowercase letters indicate modification from the wild-type sequence.
b Numbers in this column indicate position of the primers where 1 is the start of primary viral transcripts.
Fig. 1. Identification of minimum FeLV LTR-sequence required for cellular gene transactivation. The diagram on the left shows the location of the LTR
construct 61E-LTR and the other deletion constructs with respect to the FeLV LTR. Transcriptional activation of a collagenase IV promoter-reporter by the
various deletion constructs of the FeLV-LTR is shown on the right. Balb-3T3 cells were cotransfected with 1.5 g of reporter plasmid 517/62 coll-CAT
and 7.5 g of various LTR constructs, or backbone vector plasmid pGEM3, by DEAE-Dextran as described under Materials and methods. Forty hours later,
cells were harvested and an equal amount of protein from each lysate was used for CAT assays. One representative chromatogram has been presented. The
numbers on the left of the chromatogram represent fold-induction values for each LTR construct relative to the backbone plasmid pGEM3. These experiments
were repeated four times with comparable fold-induction values.
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made in these regions are shown in Fig. 2A. These mutants
were generated by overlap extension PCR using custom-
made mutagenic primers, as described under Materials and
methods, and cloned in the pGEM3Z vector (Promega).
The inserts in these clones were completely sequenced be-
fore their use in biological assays to verify that no error was
introduced during PCR amplification. As shown in Fig. 2A,
mutants H-A and H-4 had near wild-type transactivational
activity levels (13.8- to 10.1-fold versus 20.9-fold), whereas
mutants H-D, H-1, H-2, and H-3 had very low activity (3.9-
to 1.1-fold versus 20.9-fold). We next introduced the same
four-base mutation as in mutant H-D into the 61E-LTR
background (clone ED). Interestingly, we noticed that in the
context of the larger U3-LTR, this four-base mutation alone
was not enough to abrogate transactivational activity sig-
nificantly (Fig. 2B). Transactivation for the ED construct
was 5.5-fold compared to 11.2-fold for the same parental
wild-type clone 61E-LTR. We therefore constructed a total
of five more mutants on the background of the clone ED,
with consecutive four-base substitutions generated in the
region between the 5-end of clone 61E-LTR and primer
location M5 (see Fig. 1). The bases chosen for substitution
did not alter any known transcription factor-binding site
sequences. The location of these mutants and the sequence
alterations are shown in Fig. 2B, top. The transactivational
activity of these double-mutated U3-LTR clones on a co-
transfected collagenase promoter-reporter are shown in Fig.
2B, bottom. We identified three mutant U3-LTRs, ED-D2,
ED-D3, and ED-D4, which had minimal or no transactiva-
tional activity (only 1.7- to 3.0-fold compared to 11.7-fold
for the wild-type clone 61E-LTR).
Construction of a full-length virus with mutated LTR and
analysis of its gene transactivational activity
It is possible that the mutations we identified in this study
that abrogated the transactivational activity could also be
the part of a yet uncharacterized physiologically important
promoter or transcription factor-binding site. To address
this issue, we constructed a full-length virus with these
Fig. 2. Substitution mutants of the FeLV U3-LTR and analysis of their collagenase IV promoter transactivational activity. (A) Analysis of U3-LTR mutants
with a single set of substitutions. Location of mutations for clones H-A, H-D, H-1, H-2, H-3, and H-4 are shown on the U3-LTR sequence (1 designates
the RNA transcription start site). Altered bases for each clone are shown in capital letters under the clone name (on the left for clones H-D and H-2). These
mutations were all made on the LTR construct H (see Fig. 1). Transcriptional activation of a collagenase IV promoter-reporter by these mutants was analyzed
by cotransfection of the reporter and various LTR constructs, essentially as described in Fig. 1. (B) Analysis of U3-LTR mutants with two sets of substitutions.
All clones with a suffix “E” were derived from clone 61E-LTR (see Fig. 1). Clone ED, however, had only one set of substitution, as in H-D (A) on the
61E-LTR background. The double mutants ED-D1, ED-D2, ED-D3, ED-D4, and ED-D5 had the second mutations D1, D2, D3, D4, or D5, respectively, on
clone ED. The location of mutations D1, D2, D3, D4, and D5 are shown relative to the U3-LTR sequence. Altered bases for each clone are shown in capital
letters under the clone name. The transcriptional activation of a collagenase IV promoter-reporter by these double mutants was analyzed as in Fig. 1. One
representative chromatogram has been presented here. Fold-induction values for each LTR construct relative to the backbone plasmid pGEM3 are presented
at the bottom of the figure. These experiments were repeated three times with similar results.
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mutations in the LTR. We chose the LTR mutant ED-D2 for
this purpose. This mutant had a total of eight bases substi-
tuted, compared to the wild-type LTR (positions 119
through 116, and 292 through 289). We introduced
these mutations into both the 5- and the 3-LTRs of infec-
tious FeLV-A molecular clone 61E (Fig. 3A). The positions
of these mutations in the context of known transcription
factor-binding sites on the FeLV LTR are shown. The re-
construction of this LTR-mutant full-length clone (61E-
Mut) is described in detail under Materials and methods. It
is noted that because of the mechanism of the reverse
transcription process in retroviruses, it is not necessary to
replace both the LTRs for the purpose of generating infec-
tious stock virus with the same mutation in both LTRs.
However, we introduced the above mutations into both the
5- and the 3-LTRs so that we could use the plasmid DNA
in transient transfection assays and be able to interpret the
results. We verified the authenticity of clone 61E-Mut by
extensive restriction enzyme analysis and automated se-
quencing of excised fragments of both the U3-LTRs from
this full-length clone. We next tested the gene transactiva-
tional activity of 61E-Mut in transient reporter assays. This
LTR-mutant full-length FeLV proviral clone did not trans-
activate collagenase IV or MCP-1 promoter in transient
transfection assays (Fig. 3B). Comparable to our findings
using the isolated mutant LTR constructs, this mutant in-
duced the collagenase promoter by only a maximum of
1.5-fold, compared to a 44.4-fold induction by the wild-type
61E clone (Fig. 3B). Similarly, the 61E-Mut induced a
MCP-1 promoter-reporter by only 1.5-fold, compared to
20.5-fold induction by the wild-type 61E proviral clone.
Analysis of replication competence and kinetics
Next, to assess the replication competence, we trans-
fected 61E-Mut in AH927 cells and tested whether the clone
can make infectious virus particles. We used AH927 cells
which are of feline origin so that cellular environment
during replication is close to natural infection. Following
transfection in AH927 cells we monitored FeLV core anti-
gen p27 production in culture supernatant fractions by
ELISA. At 3-day intervals, cells were split at a 1:4 ratio in
fresh medium up to four passages. During this time p27
antigen levels gradually increased (data not shown). These
findings clearly indicated that the 61E-Mut clone was rep-
lication-competent and infectious. It was possible, however,
that although the mutant virus was replication competent,
the kinetics of its replication in comparison to the wild-type
virus might have been altered by the mutation. To test this
possibility, we assayed the kinetics of replication of this
mutant virus compared to the wild-type 61E virus. Infec-
tious virus stocks of both 61E and 61E-Mut were prepared
from transfected AH927 cells (from 4th passage level) and
the virus titer in each was determined by the end-point
dilution method. Actively growing AH927 cells were then
infected with an equal number of infectious units (1  104)
of the individual stocks of 61E and 61E-Mut viruses. Ki-
netics of virus replication in these cultures were monitored
by measurement of reverse transcriptase activity in the cul-
ture supernatant fractions. The cultures were maintained for
up to 18 days. As shown in Fig. 4A, the kinetics of repli-
cation of the mutant virus 61E-Mut were not significantly
different compared to the wild-type virus 61E. Except for a
slight lag in the period during early infection and spreading
(4–10 days after infection) by the mutant, the kinetic pro-
files were similar.
Effect on LTR-mutation on viral RNA production
To get a quantitative comparison of the replication of
these two viruses, we also analyzed viral RNA production
by them. We extracted total RNA from AH927 cells that
were transfected with either wild-type 61E or the LTR-
mutant 61E-Mut clones and passaged four times. The
amount of viral RNA present in these samples was analyzed
by semiquantitative RNA dot-blot assay. To avoid misin-
terpretation of the data, we included two controls in our
experiments. First, to avoid contamination of genomic
DNA, we treated RNA preparations with RNase-free
DNase. Second, to appreciate the significance of any differ-
ence in the dot-blot intensity we may see, we performed one
other set of dot-blot for loading control using DNA probe
for the ubiquitously expressed gene -actin. The dot-blot
analysis presented in Fig. 4B shows that the wild-type virus
61E and the mutant 61E-Mut expressed comparable level of
viral RNA. -Actin expression levels were the same in both
RNA preparations. This experiment thus indicated that the
LTR mutations that abrogate its transactivational activity
did not alter viral RNA expression significantly.
Maintenance of mutation during virus propagation
It was formally possible that, during the first few pas-
sages, the mutant virus 61E-Mut had reverted back to wild-
type sequence or had acquired a compensatory mutation(s)
in other parts of the LTR. Such potential sequence reversion
might then have allowed the mutant virus to grow with
replication kinetics similar to the wild-type. To address this
issue, we resequenced the entire U3-LTR region of the
61E-Mut virus following multiple passages in vitro.
Genomic DNA was isolated from 61E-Mut-infected AH927
cells that had been passaged four times. (The virus stocks
employed in the replication kinetics analyses were also
collected at this passage level.) Because analysis of RNA
from the virus particles is arguably a better representation of
the sequences that are biologically active, we also isolated
RNA from the cell-free culture supernatant fraction virus.
This RNA was then reverse transcribed and subjected to
further analysis. PCR amplified products of the entire U3-
LTR sequence from both genomic DNA and reverse-tran-
scribed RNA were cloned in the TA cloning vector and the
nucleotide sequences of multiple clones from both groups
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Fig. 3. A full-length FeLV construct with mutations in the LTR and analysis of its cellular gene transactivational activity. (A) A schematic diagram of the
FeLV LTR-mutant 61E-Mut. The two asterisks on each LTR represent the two mutations we introduced on FeLV-A infectious molecular clone 61E. Shown
underneath is the entire U3-LTR sequence of 61E, where 1 represents the beginning of LTR repeat region “R”. The locations of the known binding sites
of transcription factors LVb, Core, NF1, GRE, and FLV-1 are shown in boxes. Also shown in boxes are the two sequences we have mutated. The modified
bases in the mutant are shown in italicized letters under those two boxes. (B) Transcriptional activation of a collagenase IV and MCP-1 promoter-reporter
by 61E-Mut. Ten micrograms of full-length plasmid DNA of 61E or 61E-Mut were cotransfected with either 1.5 g of 517/62 coll-CAT or 5.0 g of
543 JE-CAT into Balb-3T3 cells and transcriptional activation was assessed as described in Fig. 1. In the control experiment, 10 g of the backbone vector
plasmid pTZ19U was cotransfected with the reporter plasmids. Wild-type and mutant LTR clones (61E-LTR and ED-D2, respectively) were also included
in this experiment. In these transfections, 5 g of the LTR or 5 g of the backbone plasmid pGEM3 were used. These experiments were repeated three times
with comparable results. One representative chromatogram has been presented here. Fold-induction values are shown at the bottom of the chromatogram.
Results for full-length clones are relative to the backbone vector pTZ19U, and for the LTR constructs are relative to the backbone vector pGEM3.
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were determined. The mutations introduced into 61E-Mut
were maintained in all clones, from both genomic DNA and
replicating virus particles. The PCR products from both
groups were also subjected to direct sequencing. We have
previously showed that direct sequencing of this nature can
detect mixed populations containing as little as 10% of a
second variety (Wei et al., 1995). Even direct sequencing
did not identify any reversion at positions 292 to 289
Fig. 4. Analysis of replication of FeLV LTR mutant 61E-Mut. (A) Replication kinetics of 61E-Mut. Actively growing AH927 cells were infected in triplicate
with 1 104 infectious units of 61E or 61E-Mut viruses, as described under Materials and methods. Culture supernatant fractions were collected immediately
after incubation with virus stock (day 1) and at other time intervals after infection, as indicated. Reverse transcriptase activity in 25 l aliquots of culture
supernatant fractions was analyzed by [32P]dTTP incorporation, as described under Materials and methods. Data shown at the bottom represent the mean
and standard deviation values for three experiments, expressed in cpm of [32P]dTTP incorporated. (B) Effect of mutation in LTR on viral RNA production
in AH927 cells. Total RNA was extracted from AH927 cells that were transfected with either wild-type 61E or the LTR-mutant 61E-Mut clones and passaged
four times. Semiquantitative RNA dot-blot assay was then performed on these two RNA samples as described under Materials and methods. RNA samples
were serially two-fold diluted and spotted on the membrane and hybridized with individual probes as indicated on the left of the boxes. The blots are
representative of two separate experiments. Amount (g) of RNA spotted on to the first and the last box are indicated at the top.
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and 119 to 116, or anywhere else in the U3-LTR (data
not shown). These findings further suggest that the muta-
tions introduced into 61E-Mut did not interfere with virus
replication. Further, AH927 cells are known to possess
endogenous FeLV-like sequences and recombinational
events could potentially take place in these cells between
these endogenous sequences and the 61E-Mut provirus.
Although we have previously shown that the endogenous
FeLV LTR-like sequences present in AH927 cells cannot
transactivate cellular gene expression (Ghosh et al., 2000),
it was possible that such recombinational events might have
helped the mutant virus to grow. The above sequence data,
however, clearly indicated that this did not happen.
Discussion
In this study we performed mutational analysis of the
FeLV-A U3-LTR and identified substitution mutants that
lost this gene transactivation activity. We introduced these
mutations into a well-characterized infectious molecular
clone of FeLV-A, 61E. The mutant virus 61E-Mut gener-
ated in this study has a total of only eight bases substituted
in the U3-LTR, with the rest of the genome identical to the
wild-type clone 61E. The inability of this mutant virus to
transactivate cellular genes such as collagenase IV and
MCP-1 is, therefore, a direct consequence of mutations in
the LTR. Further, the fact that 61E-Mut was replication
competent and kinetics of replication was almost same as
the wild-type suggested that the transactivational activity
ablating LTR mutations identified in this study did not alter
any essential transcription factor-binding sites. Therefore,
our study suggests that the promoter activity and the cellular
gene transactivational activity are separate functions of the
U3-LTR.
It is noteworthy that mutations at positions 292 to
289 identified in this study, in fact, lie outside the en-
hancer region of the LTR. In other studies LTR sequences
outside the enhancer region have also been shown to be
important for disease pathogenesis in both MuLV and
FeLVs. For example, a 23-bp GC-rich LTR sequence down-
stream of the enhancer was found to significantly influence
the disease specificity and latency of M-MuLV (Hanecak et
al., 1991). Yoshimura and colleagues have shown that a
93-bp downstream of enhancer (DEN) region in MuLV-
MCF13 is important for the induction of thymic lymphomas
by this virus (Tupper et al., 1992; Yoshimura et al., 1997,
1999). Further, Athas et al. have shown in FeLV strain
FeLV-495, isolated from feline non-T cell, non-B cell mul-
ticentric lymphomas, that a tandem triplication of 21-bp
sequence downstream of enhancer was important for dis-
ease pathogenesis (Athas et al., 1995a,b; Starkey et al.,
1998). These studies suggested that the region in question
most likely is recognized by transcription factors present in
T cells and helps in high-level transcription of the viral
genome. However, our dot-blot analysis suggests that the
eight-base sequence identified in this study does not affect
the level of transcription of the viral genome. Because our
study showed that the isolated LTR (61E-LTR) alone trans-
activated collagenase IV promoter but not the mutant LTR
(ED-D2), we believe that the expression level of viral RNA
does not play any role in the transactivational activity of the
virus. Interestingly, in other experiments we have observed
that 61E-Mut virus cannot direct transcription (unlike the
wild-type 61E virus) from reporter constructs containing a
promoter with AP-1 binding sites. This differential effect on
AP-1 DNA binding activity was also observed in reporter
assays with isolated LTRs 61E-LTR and ED-D2 (data not
shown). This information further supports the concept that
only the U3-LTR region controls the cellular gene transac-
tivational activity. The mechanism by which U3-LTR trans-
activates cellular gene expression is not understood, al-
though we have shown that this region of the LTR generates
an RNA transcript, and expression of this transcript corre-
lates with cellular gene transactivational activity (Choi and
Faller, 1995; Ghosh and Faller, 1999; Ghosh et al., 2000).
In this article, we used only reporter assays to demon-
strate the inability of the 61E-Mut virus to transactivate host
cellular genes (collagenase IV or MCP-1). We have not
tested yet whether this mutant virus affects expression of the
endogenous collagenase IV or MCP-1 genes. However, it
has been demonstrated previously that Balb-3T3 cells tran-
siently transfected with, or stably expressing a wild-type
MuLV LTR, enhances endogenous collagenase IV and
MCP-1 mRNA and protein expression (Faller et al., 1997a).
A correlation therefore exists between the reporter assays
we employed in this report and activation of expression of
the endogenous collagenase IV and MCP-1 genes. This
61E-Mut virus, therefore, will be a useful reagent in testing
the necessary or contributory role of this cellular gene
transactivation property in FeLV-induced tumorigenesis.
The transactivation-deficient mutant virus can be tested in
cats for tumorigenic potential either by direct injection of
plasmid DNA or by traditional inoculation of infectious
virus particles (Chen et al., 1998; Rohn et al., 1998). Alter-
natively, the mutated FeLV LTR can be used to replace the
wild-type LTR in an infectious Mo-MuLV clone, and the
leukemogenic potential of the resultant FeLV/MuLV chi-
meric virus can be tested in mice. Such an approach using
chimeric LTRs has already been employed successfully to
identify determinants of host range and tumorigenicity in
the LTR (Pantginis et al., 1997; Starkey et al., 1998).
Materials and methods
Cells and plasmids
Murine fibroblast Balb-3T3 cells were maintained in
DMEM supplemented with 10% donor calf serum, 2 mM
L-glutamine, and 100 g per milliliter each of penicillin and
streptomycin. The FeLV-negative feline embryo fibroblast
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AH927 cell line was maintained DMEM with L-glutamine
and antibiotics as above, but with 10% fetal calf serum. The
replication-competent full-length FeLV-A molecular clone
61E was obtained from NIH Reference Reagent Program.
The U3-LTR construct from 61E (61E-LTR) has been de-
scribed previously (Ghosh and Faller, 1999). The reporter
plasmid 517/62 collagenase CAT (517/62 Coll-
CAT) was a gift of P. Angel (Angel et al., 1988) and the
MCP-1 promoter-CAT construct (543 JE-CAT) was a gift
from A. J. van der Eb (Timmers et al., 1990).
Transfection and chloramphenicol acetyl transferase
(CAT) assays
Healthy Balb-3T3 or AH927 cells were transfected with
CsCl-banded plasmid preparations by the DEAE-dextran
method, as described previously (Ghosh and Faller, 1999).
Transfected cells were harvested 40 h later and were lysed
by quick-freezing and thawing three times. Equal amounts
of protein from clarified supernatant fractions were then
assayed for CAT activity using 14C-chloramphenicol and
acetyl-CoA, followed by thin-layer chromatographic sepa-
ration of acetylated 14C-chloramphenicol (Gorman et al.,
1982). Transfection efficiency was monitored by cotrans-
fection of 1 g of an expression plasmid for green fluores-
cent protein for each plate. To quantitate relative fold-
induction values for each sample, respective acetylated 14C-
chloramphenicol spots on the chromatogram were identified
and collected by scraping and their radioactivity was mea-
sured by liquid scintillation counting. Fold induction for any
particular LTR construct was expressed as the ratio of
acetylated 14C-chloramphenicol generated by the LTR con-
struct to that generated by the backbone vector.
DNA manipulations
5-end and 3-end deletion constructs of the U3-LTR
were made by PCR amplification of the selected region of
61E-LTR using custom primer pairs. Restriction enzyme
sites were introduced in these primers by minimal sequence
alteration. The PCR reaction mixture was first heated at
94°C for 3 min and then continued for another 30 cycles
with denaturation at 94°C for 30 s, annealing at 55°C for 1
min, and extension at 72°C for 1 min. At the end, reactions
were extended for 5 min at 72°C. Pfx platinum Taq poly-
merase with proof-reading capacity (Invitrogen) was used in
all PCR reactions. PCR products were purified from agarose
gel, digested with appropriate restriction enzyme, and
cloned into the pGEM3 vector (Promega).
Substitution mutations on the U3-LTR were made by
overlap-extension PCR, as described previously (Ho et al.,
1989). Briefly, for each mutant clone, two DNA fragments
were generated by PCR amplification on clone H using one
of the two complementary mutagenic primers and T7 or SP6
promoter primers as appropriate. These mutagenic primers
are listed in Table 1 as X-R (for 3-end primer) and X-F (for
5-end primer) for each set. The 3-primer of the first frag-
ment had complementary overlapping ends with the 5-
primer of the second fragment. PCR fragments were gel
purified and combined in a subsequent “fusion” reaction
supplemented with dNTPs, PCR reaction buffer, and Taq
DNA polymerase without any primer. The resulting fusion
product was then amplified further by PCR using T7- and
SP6-promoter primers. PCR products were then cloned into
pGEM3 vector as above. Representative clones from each
group were completely sequenced to ensure absence of
PCR-introduced errors.
Clone ED was made by overlap-extension PCR using
primers HD-F and HD-R, as above, but on the larger LTR
clone 61E-LTR. To introduce additional mutations at the
5-region of clone ED, standard PCR amplification was
performed on clone ED using primer SP6 promoter and one
of the primers D1, D2, D3, or D4 (Table 1). PCR products
were gel-purified, digested with PstI and EcoRI, and cloned
into the same sites of pGEM3.
Construction of full-length virus
To make transactivational activity-deficient full-length
FeLV, specific mutations present in clone ED-D2 were
introduced into the replication-competent FeLV-A molecu-
lar clone 61E (Overbaugh et al., 1988). First, 5-half and
3-half subclones from 61E were made around the unique
BamHI site at position 5317 in the pTZ19U plasmid (U.S.
Biochemicals). A 3-end LTR subclone (from Pstl site at
position 7992 to the EcoRI site in the polylinker of the
3-half subclone) with the two mutations described above
was then constructed by overlap-extension PCR. HD-F/T7
and HD-R/SP6 primer pairs were used in PCR reactions on
templates ED-D2 and 3-half subclone, respectively. The
presence of correct mutations and the absence of PCR-
introduced errors were confirmed by sequence analysis. The
341-bp Pstl-Smal fragment from this 3-end LTR subclone
(containing two mutations as in ED-D2) was then intro-
duced into the U3-R region of both 5-half and 3-half
subclones of 61E by standard molecular cloning technique.
Finally, the mutated 5-half and 3-half subclones were
rejoined at the unique BamHI site to generate a full-length
FeLV with two sets of mutations in both of the LTRs
(61E-Mut).
Replication kinetics assay
To generate virus stocks for wild-type FeLV-A (61E)
and the transactivation-deficient FeLV-A mutant (61E-
Mut), 10 g of individual plasmids was transfected in
AH927 cells by DEAE-dextran method. Cells were split 2
days after transfection and then at every 3-day interval.
Productive infection was monitored by detection of FeLV
capsid protein p27 in the culture supernatant fractions by
commercially available p27 antigen ELISA kit (Synbiotics
Corp., La Jolla, CA). At passage four, when the P27 antigen
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level was significantly high, culture supernatants were clar-
ified by low-speed centrifugation and stored at 70°C in
1-ml aliquots. The infectious titers of these stocks were
measured on AH927 cells by the endpoint dilution method,
as described previously (Bechtel et al., 1994; Klement and
Nicolson, 1977). For the analysis of replication kinetics, 5
 105 actively growing AH927 cells were seeded onto
100-mm plates. On the following day, cells were incubated
in triplicate plates with 1  104 infectious units of individ-
ual virus stocks in a 2-ml volume in the absence of poly-
brene for 4 h. Cells were then washed twice in PBS and
refed with fresh growth medium. Supernatant fractions from
these cultures were collected immediately after addition of
the growth media and then on every third day for reverse
transcriptase assay. During each sample collection, the cells
were split at a density of 5  105 cells per 100-mm plate to
maintain the same relative cell density during the course of
the experiment.
Reverse transcriptase (RT) assay
Reverse transcriptase activity in the culture supernatant
fractions was measured directly without further virus con-
centration. Twenty-five microliter aliquots of clarified cul-
ture supernatant fractions were mixed with an equal volume
of reaction cocktail [50 mM Tris–HCl, pH 8.0; 60 mM
NaCl; 10 mM MgCl2; 10 mM DTT; 0.05% Igepal (NP-40
substitute); and 3 Ci/ml [32P]dTTP (3000 Ci/mmol, Per-
kin–Elmer.)] Each reaction contained 2 g poly(rA-
dT)12–18 as the template. Reactions were set up in a micro-
titer plate and incubated at 37°C for 90 min. Reaction
mixtures were then spotted onto individual 2.5-cm-diameter
DE81 filter disks (Whatman International), air-dried, and
washed two times for 5 min each in 2 SSC (1 SSC is
0.15 M NaCl and 0.015 M sodium citrate, pH 7.0). Filters
were rinsed with ethanol and air-dried before quantification
by liquid scintillation counting.
RNA dot-blot assay
RNA samples for the dot-blot assay were obtained from
AH927 cells that were transfected with either wild-type 61E
or the LTR-mutant 61E-Mut clones and passaged four
times. Cells were harvested by scraping, washed once in
cold PBS and RNA was extracted by Trizol extraction
method according to the manufacturer’s protocol (Invitro-
gen). DNA contamination in the RNA samples was re-
moved by treating them with RQ1 RNase free DNase (Pro-
mega) at a concentration of 0.1 U/l for 30 min at 37°C
followed by phenol-chloroform extraction and ethanol pre-
cipitation. RNA samples were finally suspended in DEPC-
treated water and quantitated by spectrophotometer. RNA
samples were serially two-fold diluted in water and 2.5 l
was spotted onto positively charged nylon membrane
(BrightStar-Plus, Ambion), air-dried, and immobilized by
exposure to UV light in a UV Stratalinker (Stratagene)
(1200 J/30 s). Membranes were prehybridized with Ex-
press-Hyb solution (Clontech) at 68°C for 40 min in a
rotisserie hybridization oven. Individual prehybridized
membranes were then hybridized with specific probes in
fresh Express-Hyb solution containing 2.0  106 cpm/ml
probe at 68°C for 1 h. Initially, membranes were washed at
room temperature for 15 min with 2 SSC containing
0.05% SDS. Next, membranes were washed in 1 SSC
containing 0.1% SDS at 50°C for 40 min with repeated
change of washing solution. Membranes were then air dried,
wrapped in plastic, and exposed to X-ray films. Individual
probes were prepared by Random Primer DNA labeling
system (Invitrogen) using 32P-labeled dCTP according to
manufacturer’s protocol. A 320-bp fragment of -actin gene
from AH927 genomic DNA was PCR amplified using
primer pairs: ACT-F: 5-GCTCGTCGTCGACAACG-
GCTC-3; ACT-R: 5-CAAACATGATCTGGGTCATCT-
TCTC-3, and used as template. Virus-specific probe was
prepared using a 9.5-kb EcoRI fragment from clone 61E as
template.
RT-PCR and sequence analysis
To isolate RNA from viral particles, 10-ml aliquots of
cell-free culture supernatant fractions from infected AH927
cells were centrifuged at 100,000 g for 1 h. AH927 cells
were transfected with 61E or 61E-Mut proviruses by the
DEAE-dextran method as described above and propagated
up to four passages prior to harvesting virus particles. Virus
particles were disrupted with 50 l proteinase K digestion
buffer (10 mM Tris–HCl, pH 7.5; 5 mM EDTA; 0.1% SDS;
100 g/ml proteinase K) for 15 min at 37°C and then
extracted with phenol-chloroform and ethanol precipitated.
All RNA preparations were treated with RQ1 RNase-free
DNase (Promega Corp.) at a concentration of 0.1 U/ml for
30 min to remove any residual genomic DNA contamina-
tion. First-strand cDNA synthesis was carried out using a
SuperScript Preamplification System for First-Strand cDNA
kit from Invitrogen, using primer P8 (Table 1). The template
cDNAs obtained were PCR-amplified using primers P1 and
P3 (Table 1). PCR products were analyzed on 1% agarose
gel and appropriate-sized amplified products were purified
from the agarose gel. Approximately 100 ng of the product
was cloned in a TA cloning vector (Invitrogen), according
to the manufacturer’s protocol. Individual TA clones were
tested for their authenticity by restriction-enzyme digestion
and the inserts of select clones were then completely se-
quenced from both ends using an ABI 3700 automated
sequencer. A fraction of the band-purified PCR products
was also directly sequenced. Two FeLV-specific sense and
antisense primers (P2 and M10, respectively; Table 1) were
used for sequence analysis so that overlapping sequence
data can be generated. Chromatogram files generated were
aligned by Sequencer 3.0 program (Gene Codes, Ann Ar-
bor, MI) and analyzed for sequence mismatch.
To isolate genomic DNA, infected cells were lysed in the
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presence of proteinase K digestion buffer for 30 min, fol-
lowed by phenol-chloroform extraction. DNA from the ly-
sate was spooled out in the presence of cold ethanol.
Genomic DNA was then subjected to PCR amplification
and TA-cloning as described above. Sequence analysis of
the PCR product and individual TA clones were done es-
sentially as above.
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